Analyst ratings and price targets can significantly influence a stock's performance. In this case, Jefferies, a reputable financial firm, has initiated coverage on RayzeBio with a Buy rating and a price target of $35. This suggests that they believe the stock is undervalued at its current price and has the potential to reach or exceed $35. This positive outlook could attract more investors to the stock, driving up its price in the short term.